Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

Abstract excerpt

Abstract: Approximately a fifth of ovarian carcinoma (OC) is associated with inherited germline mutations, most commonly in the DNA repair genes BRCA1 or BRCA2 ( BRCA ). BRCA1 - and BRCA2 -associated OCs have historically been described as a single subgroup of OC that displays a distinct set of characteristics termed the “BRCAness” phenotype. The hallmarks of this phenotype are superior clinical outcome and...

Topics

Join the communities discussing this publication.

• BRCA gene mutations in cancer
• Ovarian cancer diagnosis and treatment
• PARP inhibition in cancer therapy